Dibutyryl-cAMP (Bucladesine sodium)
This product is for research use only, not for human use. We do not sell to patients.
For small sizes, please check our retail website as below: www.invivochem.com
| Size | Price | Stock |
|---|---|---|
| 5g | $1000 | In Stock |
| 10g | $1650 | In Stock |
| 20g | $2475 | In Stock |
: Cat #: V1846 CAS #: 16980-89-5 Purity ≥ 98%
Description: Bucladesine sodium (also known as Dibutyryl-cAMP sodium), the sodium salt of Bucladesine, is a cell-permeable PKA activator and a cAMP analog that mimics the action of endogenous cAMP.
Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 491.37 |
|---|---|
| Molecular Formula | C18H23N5NaO8P |
| CAS No. | 16980-89-5 |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 98 mg/mL (199.4 mM)r |
| Water: 98 mg/mL (199.4 mM)r | |
| Ethanol: N/A | |
| Solubility In Vivo | 10% DMSO+ddH2O: 30 mg/mL |
| Synonyms | dbcAMP; DC-2797; Dibutyryl-cAMP sodium salt; DC2797; Sodium dibutyryl cAMP; DC 2797; Bucladesine sodium; DbcAMP sodium; Actosin; Sodium Dibutyryl cAMP; Cyclic dibutyryl-AMP sodium salt Chemical Name: sodium (4aR,6R,7R,7aR)-6-(6-butyramido-9H-purin-9-yl)-7-(butyryloxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide SMILES Code: O=P1(OC[C@H]2O[C@H]([C@@H]([C@@H]2O1)OC(CCC)=O)N3C4=NC=NC(NC(CCC)=O)=C4N=C3)[O-].[Na+] |
| Protocol | In Vitro | Both choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) mRNA increased approximately fourfold after treatment of PC12 cells with Bucladesine (dibutyryl cyclic AMP; dbcAMP). ChAT and PKA activity are also increased by Bucladesine |
|---|---|---|
| In Vivo | Intrahippocampal infusion of Bucladesine into the CA1 region (male Albino-Wistar rats) can cause an improvement in spatial memory in maze task. Bilateral infusion of 10 μM and 100 μM Bucladesine leads to a significant reduction in escape latency and travel distance (showing an improvement in spatial memory). Bucladesine via activation of PKA and induction of cAMP/PKA pathway improved spatial memory retention |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.0351 mL | 10.1756 mL | 20.3513 mL | 40.7025 mL |
| 5mM | 0.4070 mL | 2.0351 mL | 4.0703 mL | 8.1405 mL |
| 10mM | 0.2035 mL | 1.0176 mL | 2.0351 mL | 4.0703 mL |
| 20mM | 0.1018 mL | 0.5088 mL | 1.0176 mL | 2.0351 mL |
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start)
×
Volume(start)
=
Concentration(final)
×
Volume(final)
This equation is commonly abbreviated as: C1 V1 = C2 V2
Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg
Average weight of animals g
Dosing volume per animal µL
Number of animals
Step Two: Enter the in vivo formulation
%DMSO
+
%
+
%Tween 80
+
%ddH2O
Calculation Results:
Working concentration:
mg/ml;
Method for preparing DMSO master liquid:
mg
drug pre-dissolved in
µL
DMSO(Master liquid concentration
mg/mL)
,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:
Take
µL
DMSO master liquid, next add
µL
PEG300, mix and clarify, next add
µL
Tween 80,mix and clarify, next add
µL
ddH2O,mix and clarify.
Note:
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.